NCT03776058 is a Phase 2 clinical trial of Cinacalcet in Primary Hyperparathyroidism, sponsored by Amgen.

Who is sponsoring NCT03776058?

NCT03776058 is sponsored by Amgen.

What drugs are being tested in NCT03776058?

Interventions in NCT03776058: Cinacalcet, Placebo.

What condition does NCT03776058 study?

NCT03776058 studies Primary Hyperparathyroidism.

Is NCT03776058 still recruiting?

NCT03776058 is currently completed. Last updated 14 December 2018.

Last reviewed 2018-12-14 · How we verify

NCT03776058

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

Completed Phase 2 Last updated 14 December 2018

What this trial tests

Phase 2 trial testing Cinacalcet in Primary Hyperparathyroidism in 10 participants. Completed in 26 December 2000.

Timeline

15 June 2000

Primary endpoint
26 December 2000

26 December 2000

Quick facts

Lead sponsor	Amgen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	10
Start date	15 June 2000
Primary completion	26 December 2000
Estimated completion	26 December 2000

Drugs / interventions tested

Cinacalcet (CINACALCET) — full drug profile →
Placebo

Conditions studied

Primary Hyperparathyroidism — all drugs for Primary Hyperparathyroidism →

Sponsor

Amgen — full company profile →

Who can join

18 and older, any sex, with Primary Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objectives were to assess the safety and tolerability of twice daily (BID) doses of 65 mg cinacalcet administered orally to adults with primary HPT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cinacalcet

Trials testing the same drug.

NCT07122401 — Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism · Phase 3 · recruiting
NCT05926570 — Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis · Phase 4 · completed
NCT05663411 — A Study of SHR6508 in Secondary Hyperparathyroidism · Phase 2 · unknown
NCT03994172 — Novel Combination Therapy for Osteoporosis in Men · Phase 4 · active not recruiting
NCT03299244 — Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SH · Phase 3 · completed

Other recruiting trials for Primary Hyperparathyroidism

Currently open trials in the same condition.

NCT07444723 — Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors · Phase 2, PHASE3 · recruiting
NCT06859580 — Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism · Phase 4 · recruiting
NCT05997810 — Parathyroid Tumor Clonal Status · recruiting
NCT05761743 — Glycemic Control, Type II Diabetes, Parathyroidectomy · active not recruiting
NCT07138820 — 18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased · NA · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03776058 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 14 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03776058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing